Tocilizumab-associated multifocal cerebral thrombotic microangiopathy
Tocilizumab is a humanized monoclonal antibody that targets the interleukin-6 receptor (IL-6-R). It is approved for use in moderate to severe refractory rheumatoid arthritis and more recently has been found to be effective in treating neuromyelitis optica.1 Common side effects include raised hepatic...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Academy of Neurology
2016
|